A detailed history of Aptus Capital Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Aptus Capital Advisors, LLC holds 83,343 shares of ABBV stock, worth $14.7 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares
83,343
Previous 68,886 20.99%
Holding current value
$14.7 Million
Previous $11.8 Million 39.3%
% of portfolio
0.26%
Previous 0.23%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$163.84 - $199.33 $2.37 Million - $2.88 Million
14,457 Added 20.99%
83,343 $16.5 Million
Q2 2024

Jul 31, 2024

BUY
$154.79 - $180.76 $2.15 Million - $2.51 Million
13,887 Added 25.25%
68,886 $11.8 Million
Q1 2024

May 15, 2024

BUY
$159.82 - $182.1 $746,838 - $850,953
4,673 Added 9.29%
54,999 $10 Million
Q4 2023

Feb 13, 2024

SELL
$137.6 - $154.97 $666,534 - $750,674
-4,844 Reduced 8.78%
50,326 $7.8 Million
Q3 2023

Nov 08, 2023

BUY
$133.59 - $154.65 $116,757 - $135,164
874 Added 1.61%
55,170 $8.22 Million
Q2 2023

Aug 11, 2023

SELL
$132.51 - $164.9 $1.71 Million - $2.12 Million
-12,873 Reduced 19.17%
54,296 $7.32 Million
Q1 2023

May 09, 2023

BUY
$144.61 - $166.54 $535,780 - $617,030
3,705 Added 5.84%
67,169 $10.7 Million
Q4 2022

Feb 13, 2023

BUY
$138.31 - $165.87 $1.09 Million - $1.31 Million
7,903 Added 14.22%
63,464 $10.3 Million
Q3 2022

Nov 02, 2022

SELL
$134.21 - $153.93 $2.34 Million - $2.69 Million
-17,458 Reduced 23.91%
55,561 $7.46 Million
Q2 2022

Jul 29, 2022

BUY
$137.62 - $174.96 $3.7 Million - $4.71 Million
26,921 Added 58.4%
73,019 $11.2 Million
Q1 2022

May 04, 2022

SELL
$131.98 - $163.75 $698,834 - $867,056
-5,295 Reduced 10.3%
46,098 $7.47 Million
Q4 2021

Feb 02, 2022

BUY
$107.43 - $135.93 $764,149 - $966,870
7,113 Added 16.06%
51,393 $6.96 Million
Q3 2021

Oct 27, 2021

BUY
$106.4 - $120.78 $933,447 - $1.06 Million
8,773 Added 24.71%
44,280 $4.78 Million
Q2 2021

Jul 27, 2021

BUY
$105.21 - $117.21 $472,813 - $526,741
4,494 Added 14.49%
35,507 $4 Million
Q1 2021

May 06, 2021

BUY
$102.3 - $112.62 $83,272 - $91,672
814 Added 2.7%
31,013 $3.36 Million
Q4 2020

Feb 10, 2021

SELL
$80.49 - $108.67 $21,168 - $28,580
-263 Reduced 0.86%
30,199 $3.24 Million
Q3 2020

Oct 19, 2020

BUY
$85.91 - $100.83 $100,085 - $117,466
1,165 Added 3.98%
30,462 $2.67 Million
Q2 2020

Jul 22, 2020

BUY
$73.37 - $98.18 $117,978 - $157,873
1,608 Added 5.81%
29,297 $2.88 Million
Q1 2020

May 07, 2020

SELL
$64.5 - $97.79 $1.84 Million - $2.8 Million
-28,602 Reduced 50.81%
27,689 $2.11 Million
Q4 2019

Feb 10, 2020

BUY
$72.13 - $90.25 $578,626 - $723,985
8,022 Added 16.62%
56,291 $4.98 Million
Q3 2019

Nov 12, 2019

BUY
$62.98 - $75.72 $1.79 Million - $2.16 Million
28,501 Added 144.18%
48,269 $3.66 Million
Q2 2019

Aug 13, 2019

BUY
$65.7 - $83.98 $20,104 - $25,697
306 Added 1.57%
19,768 $1.44 Million
Q1 2019

May 15, 2019

BUY
$77.14 - $90.79 $96,425 - $113,487
1,250 Added 6.86%
19,462 $1.57 Million
Q4 2018

Feb 12, 2019

BUY
$77.85 - $96.01 $1.42 Million - $1.75 Million
18,212 New
18,212 $1.68 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $313B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Aptus Capital Advisors, LLC Portfolio

Follow Aptus Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aptus Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aptus Capital Advisors, LLC with notifications on news.